Showing posts sorted by relevance for query nktr. Sort by date Show all posts
Showing posts sorted by relevance for query nktr. Sort by date Show all posts

Sunday, September 1, 2019

NKTR- 214 (bempegaldesleukin) with Opdivo - PERHAPS the results from the PIVOT trial for melanoma patients were LOWER than they should have been? Meaning if the company who makes it (Nektar) gets its act together patients may demonstrate an even better response????


I've been reporting on NKTR-214 (bempegaldesleukin) since 2013, the PIVOT trial in particular.  The drug was also discussed at ASCO this year, with my report on that (with links to prior reports) here:  New Stuff!! Treatment options and current trials for melanoma patients! The first installment of this year's ASCO review.

Here's most of what I wrote from ASCO:

I first reported on NKTR in 2013.  Click here for that report as well as abstracts and analysis from 2018.  After examining the Phase 1 and Phase 2 reports of the PIVOT trial I wrote:

"...back to NKTR-214 combined with nivo.  Like many drugs/trials in cancer/melanoma world, the Phase 1 trials were super promising.  Phase II results were a little less so.  Responses as noted in the article were "(ORR) of 50% in treatment-naïve patients with melanoma, including an ORR of 42% in PD-L1–negative patients".  We have already determined that treatment naive patients tend to have the best responses.  But even so, 50% beats 40%.  Additionally, we also know that PD-L1 status has not been particularly definitive in attaining responses to anti-PD-1 drugs, but it is still good to note a 42% ORR in PD-L1 negative patients and that side effects were really no worse in this combo than when anti-PD-1 is taken alone.  So....

I still hold out hope ~ for vaccines, for IDO-inhibitors, and the current responses to NKTR-214 combined with nivo to hold.  BUT!  Unlike Melanoma Big Dogs in their ivory towers....we canaries in the coalmines...the ratties...you and me...can't afford to pontificate on the hypothetical.  We have to deal with the real live results that are happening for real.  Today.  To us."


That's how I look at melanoma research!!!!   ALWAYS! Now....this from ASCO:

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).  2019 ASCO.  Nikhil, Khushalani, Diab, .... Sznol, Long.  J Clin Oncol 37, 2019 (suppl; abstr TPS9601)

Background: Standard of care for pts with previously untreated, unresectable or metastatic MEL includes checkpoint inhibitors.Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to provide sustained signaling through the IL-2 βγ receptor to activate and proliferate effector CD8+ T and NK cells over T-regulatory cells in the tumor (Hurwitz ME et al. ASCO GU 2017). In the dose-expansion phase of the phase 1/2 PIVOT-02 trial, bempegaldesleukin + NIVO was well tolerated at the recommended phase 2 dose (RP2D; bempegaldesleukin 0.006 mg/kg IV Q3W + NIVO 360 mg IV Q3W), and previously untreated pts with MEL receiving the RP2D achieved an objective response rate (ORR) of 20/38 (53%) and a complete response of 9/38 (24%) by independent radiology review (Diab A et al. SITC 2018). Presented is the design of the first phase 3 trial in the bempegaldesleukin + NIVO development program in pts with previously untreated, unresectable or metastatic MEL. Methods: Thisphase 3, randomized, open-label study aims to evaluate the effectiveness, safety, and tolerability of bempegaldesleukin + NIVO (NCT03635983).Eligible pts are greater that/= to 2 y with histologically confirmed stage III (unresectable) or stage IV MEL and ECOG PS less that/= to 1 or Lansky PS greater than/= to 80% (minors 12-17 y). Pts are ineligible if they have active brain or leptomeningeal metastases, uveal MEL, or a recurrence within 6 mo of completing adjuvant treatment with any approved agent. Pts will be stratified by PD-L1 status (measured using PD-L1 IHC 28-8 pharmDx), BRAF mutation status, and lactate dehydrogenase level, and will be randomized to receive bempegaldesleukin 0.006 mg/kg IV Q3W + NIVO 360 mg IV Q3W or NIVO 360 mg IV Q3W up to 24 mo, or until progression or unacceptable toxicity (N ~ 764). Primary endpoints are ORR and progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS). Secondary endpoints include ORR and PFS by investigator, ORR and PFS by BICR in biomarker population, OS in biomarker population, and safety. Additional endpoints include pharmacokinetics and quality-of-life assessment. Clinical trial information: NCT03635983

So, this is an open and recruiting trial.  It is randomized.  Some folks will be getting the NKTR-214 drug with nivo, some will get nivo only.  Prior ORR of 53% is better than the usual of about 40% to anti-PD-1 products given alone, but about equal to the ipi/nivo combo.  If the side effects of this combo is less than those caused by ipi/nivo, that could be a good thing.  Lots of the usual melanoma peeps are excluded.  But, there you go.  

So that's where I thought I'd left bempegaldesleukin and nivo.  Seriously, who names this shit???  Anyhow ~ there's more, and it seriously falls in a GOOD NEWS/BAD NEWS category.  Here's a link to the report:  

From FiercePharma, August 2019: Faulty manufacturing trips up Nektar's Bristol-partnered cancer drug in crucial trial  

Which states in part:   


Could a manufacturing mix-up be as detrimental as the fact that a drug simply doesn’t work? Nektar learned the answer the hard way with its Bristol-Myers Squibb-partnered experimental cancer therapy. On Thursday, Nektar CEO Howard Robin went to great lengths to explain why response rates dropped in the second stage of a clinical trial testing NKTR-214 (bempegaldesleukin) in tandem with Bristol's Opdivo.  But in a nutshell, some patients received substandard batches of the Nektar drug, he told analysts during a conference call. And unsurprisingly, those bad batches didn't work as well.

According to Robin, Nektar ran an analysis of all 22 lots of bempeg it had produced and found that two lots—lots 2 and 5—were out of specification, though they had passed release controls under old assays. The team noted correlations between patients who started treatment with the two problematic lots and a lower response rate during the PIVOT-02 trial as compared with the other two lots used in the study.  Specifically, newly diagnosed melanoma patients who started with lots 2 and 5 saw 36% of their tumors respond to the treatment at best, with a complete response rate of 27%. The others posted response rates at 75% and 44%, respectively, Nektar’s R&D chief Stephen Doberstein said during the call. In the trial's first-line urothelial cancer cohort and first-line renal cell carcinoma cohort, similar differences were observed.  Management attributed the mess-up to a single suboptimal batch of intermediate that was used to produce only lots 2 and 5. The company found that bad batch using new quality control assays, Robin said.  And Robin promised that Nektar now has the problem under control.  “As a result of this discovery, we have developed a comprehensive control strategy to limit variances in raw materials, intermediates and the final product in our manufacturing, and this is being validated for commercial-scale manufacturing,” he said, adding that the company has also shaken up its CMC leadership.

The BAD NEWS:  Seriously, Nektar and Mr. Robin CEO man???????  We didn't ask you to change a light fixture or install brakes in our car.  We didn't count on you to do brain surgery, cook us a meal, teach our children to read, repair a computer or put a satellite into space.  We EXPECTED you to do what you SAID you knew how to do.  Make a specific drug, that you eff'n named bempegaldesleukin, they way you said you would, in the strength you said it would be, in a consistent and safe manner for use in HUMAN BEINGS!!!!!!!!!!!!!  We didn't FORCE you to do that job!  YOU SIGNED UP FOR IT!!!!!!!!!!! Good grief!  WTF??????????????!!!!!!!!!!!!!!

On the GOOD NEWS side, perhaps ~ if Mr. Robin CEO man can get his Nektar shit together, and actually make NKTR-214 as it should be - in a safe, consistent, reproducible manner - response rates in melanoma and renal cell carcinoma patients may be much improved on the nivo combo.  To the tune of:   "Newly diagnosed melanoma patients who started with lots 2 and 5 saw 36% of their tumors respond to the treatment at best, with a complete response rate of 27%. The others posted response rates at 75% and 44%, respectively" per the report above.

It is one crazy world.  Being sick should be enough - but no!!!  Hang in there ratties.  You are the best and we thank you. - c

Tuesday, June 5, 2018

ASCO 2018 - PIVOT, PIVOT, PIVOT!!!!! (Sorry, FRIENDS flashback to Ross moving a couch in a stairwell!!!) But, really - NKTR-214 plus nivo


Okay.  SO, yeah...the trial's name gave me major FRIENDS flashbacks....but all 4 of my boys (B, J, Eric, and Ed) sent me the bones of this report in varied forms!  There was this...

NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. Diab, Hurwitz, Cho, … Sznol. ASCO 2018.

PIVOT is an ongoing, open-label, phase 1/2 study of NKTR-214 (214; CD122-biased agonist) plus PD-1 inhibitor nivolumab (N) in patients (pts) with advanced cancers (MEL, RCC, NSCLC, TNBC, and UC). 214 monotherapy increases newly proliferative CD8+ T cells in tumors and increases cell surface PD-1 and PD-L1 expression, demonstrating a potentially synergistic mechanism with anti-PD-1 therapy.Methods:In P1 dose escalation, pts received 214 (0.003, 0.006 or 0.009 mg/kg) with N (240 mg or 360 mg) administered IV as outpatient Q2W or Q3W; in P2 expansion, the RP2D of 214 (0.006 mg/kg) with N (360 mg) Q3W was administered concurrently. Response was assessed Q8W by RECIST v1.1. Matched tumor samples were evaluated for changes from baseline in immune cell populations, gene expression, and T cell receptor repertoire. Tumor baseline and on treatment PD-L1 protein expression was assessed (28-8 IHC assay).Results:As of 7FEB2018, 162 pts (P1, n = 38; P2, n = 124) were evaluable for safety. The most common TRAEs of all grades at the RP2D ( > 25%) in pts were flu-like symptoms (63%), fatigue (39%), rash (38%) and pruritus (30%). G3+ TRAEs at the RP2D were 11%. No pts discontinued treatment or died from TRAEs. A total of 60 IO-treatment naïve stage IV pts (P1, n = 30; P2, n = 30) were efficacy evaluable (≥1 scan) (23 MEL, 24 RCC, 6 NSCLC, 4 UC, 3 TNBC). 22/30 P2 pts had only 1 scan. ORR (CR+PR) and DCR (CR+PR+SD) in 23 MEL (1L) pts was 52% and 78%. 18/23 MEL pts had known PD-L1 status. ORR was 5/9 (56%) for PD-L1(+) pts and 4/9 (44/%) for PD-L1(-) pts. ORR and DCR in 24 RCC (1L) pts was 54% and 79%. 20/24 RCC pts had known PD-L1 status. ORR was 4/7 (57%) for PD-L1(+) pts and 7/13 (54%) for PD-L1(-) pts. ORR and DCR in 6 NSCLC (1-2L) pts was 50% and 67%. 5/6 pts had known PD-L1 status. ORR was 3/5 (60%) in PD-L1(-) pts. ORR and DCR in 4 UC (1L) was 75% and 100%. ORR/DCR in 3 TNBC (1- 2L) pts was 33%. In 60 evaluable pts, 32/32 responses are ongoing (0.3+ to 12.0+ mos) with 45/60 pts still on treatment.Conclusions:214 plus N was well-tolerated with no TRAE discontinuations. Preliminary efficacy shows encouraging ORR/DCR with responses observed in 5 of 5 tumor types in I-O treatment naïve 1-2L pts. Updated data to be presented. Clinical trial information: NCT02983045

OR.....depending on how you like to read your data...there is this:

OncLive - NKTR-214/Nivolumab Efficacy Sustained in Phase II Findings

Combining the CD122-biased cytokine NKTR-214 with the PD-1 inhibitor nivolumab (Opdivo) showed promising antitumor activity, particularly in PD-L1–negative patients, according to updated data from the phase I/II PIVOT-02 trial presented at the 2018 ASCO Annual Meeting.

Data were presented from the phase II dose expansion part of the study demonstrating an overall response rate (ORR) of 50% in treatment-naïve patients with melanoma, including an ORR of 42% in PD-L1–negative patients. The overall ORR and PD-L1–negative ORR were 46% and 53%, respectively, in previously untreated patients with renal cell carcinoma (RCC). Among cisplatin-ineligible patients with urothelial carcinoma receiving frontline treatment, the ORR was 60% both overall and in PD-L1–negative patients.  

“Prespecified efficacy criteria were achieved [in the frontline setting] in melanoma, renal cell carcinoma, and cisplatin-ineligible urothelial carcinoma, which support the evaluation of NKTR-214 plus nivolumab in registrational trials,” lead investigator Adi Diab, MD, from the MD Anderson Cancer Center, said during his presentation of the results.

“Robust translational data confirm the rational for activation of the immune system in the tumor microenvironment with a conversion of PD-L1–negative tumors to PD-L1 positive on treatment,” Adi added. 

Phase I data for the dose escalation cohort of PIVOT-02 were previously presented at the 2017 SITC Annual Meeting. At the time of that analysis, 38 total patients with melanoma (n = 11), RCC (n = 22), and non–small cell lung cancer (NSCLC; n = 5) had received treatment with the combination. 

In the dose-escalation portion of trial, patients received nivolumab at 240 mg every 2 weeks (Q2W) or at 360 mg every 3 weeks (Q3W) with NKTR-214 at 0.003 or 0.006 mg/kg Q2W or Q3W. The identified recommended phase II dose for NKTR-214 was 0.006 mg/kg Q3W with nivolumab at 360 mg Q3W.

At ASCO, Diab first presented updated data on these cohorts, which had a cutoff of November 2, 2017, for the SITC results, and May 29, 2018, for the ASCO findings.

For the frontline cohort of patients with stage IV melanoma, the ORR was sustained between the SITC and ASCO results at 64% (7 of 11 patients). The disease control rate (DCR) was 91% (n = 10). The ORR among PD-L1–negative patients (expression <1 4="" 5="" 60="" 67="" 6="" among="" and="" expression="" nbsp="" of="" patients="" pd-l1="" positive="" span="" was="">

Among the frontline cohort of patients with stage IV RCC, the ORR at SITC was 46% (6 of 13 patients) and the DCR was 85% (11 of 13 patients). At the ASCO update, there was an additional patient, and the ORR was 71% (10 of 14 patients), with a DCR of 79% (n = 11). Five of 8 (63%) PD-L1–negative patients had a response and the ORR was 80% (4 of 5 patients) in the PD-L1–positive group. The PD-L1 status was unknown for 1 patient. 

For the patients with stage IV NSCLC, the ORR and DCR at SITC were both 75% (n = 3) among 4 patients receiving second-line therapy. The ASCO data included 1 extra patient receiving frontline treatment and the updated ORR was 60% (n = 3), with a DCR of 80% (n = 4). All 3 responders were PD-L1 negative, with 2 achieving a complete response.


The phase II dose expansion cohort of the trial has a target enrollment of approximately 330 patients. The cohorts include melanoma (first through third line), RCC (first through third line), NSCLC (first and second line, as well as second line immune-relapsed/refractory), urothelial carcinoma (first line cisplatin ineligible, as well as second and third line), and triple-negative breast cancer (first and second line).

At ASCO, Diab presented data for the 3 cohorts that have met the trial’s prespecified efficacy criteria: frontline melanoma, frontline RCC, and frontline cisplatin-ineligible urothelial carcinoma.

“The other tumor types continue to be at various stages of enrollment and the data has not yet met the prespecified stopping criteria either for futility or efficacy,” explained Diab.

Forty-one patients have been enrolled in the frontline melanoma cohort, 24 are male and 17 are female. The median patient age was 63 years (range, 22-80). Three-fourths of patients had an ECOG performance score of 0. Twenty patients were PD-L1 positive, 14 were PD-L1 negative, and the status was unknown for 7. Regarding BRAF status, 36.6% were positive, 61.0% were wild-type, and 2.4% were unknown.

Diab reported data for 28 of these patients, among whom 14 responded, for an ORR of 50%. The DCR was 71% (n = 20). The median time on study for these patients was 4.6 months. The ORR was 42% (5/12) among PD-L1–negative patients and 62% (8/13) among PD-L1–positive patients. PD-L1 status was unknown for 3 patients.

The frontline RCC cohort had enrolled 48 patients, comprising 10 females and 38 males. The median age was 61 years (range, 40-78). The ECOG performance score was 0 for 60.4% of the patients and 1 for 39.6%. The PD-L1 status was unknown for 4 patients, 30 were negative, and 14 were positive.

At ASCO, Diab shared findings for 26 patients from this cohort. The ORR was 46% (n = 12) and the DCR was 77% (n = 20). The median time on study was 5.6 months. The ORR was 53% (9/17) for PD-L1–negative patients and 29% (2/7) for PD-L1–positive patients. PD-L1 status was unknown for 2 patients.

Sixteen patients had been enrolled in the frontline cisplatin-ineligible urothelial carcinoma group, comprising 5 females and 11 males. The median patient age was 70 years (range, 54-83). Six patients had an ECOG performance score of 0 and 10 had a score of 1. There were 7 PD-L1–positive patients, 7 PD-L1–negative, and 2 whose status was unknown.

Diab reported data for 10 of these patients. The ORR was 60% (n = 6) and the DCR was 70% (n = 7). The median time on study was 3.9 months. The ORR was 60% (3 each) among the 5 PD-L1–negative patients and the 5 PD-L1–positive patients.

Safety data were available for 283 patients treated at the recommended phase II dose. Grade ≥3 treatment-related adverse events (AEs) occurred in 14.1% of patients, including hypotension (n = 5), syncope (n = 5), increased lipase (n = 4), rash (n = 4), and dehydration (n = 3).

Immune-mediated grade ≥3 AEs occurred in 3.5% of patients. One patients died of grade 5 pneumonitis related to nivolumab. The patients had NSCLC previously treated with carboplatin/pemetrexed and a history of brain metastases.

...and this....

ASCO 2018 - NKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT  (This link gives you all the nifty slides from the ASCO presentation!)

So here's the gist.  We already know that urothelial cancers and melanoma are odd bed fellows.  In my own experience, my first oncologist, with tears in his eyes said, "Oh, I hate telling patients that they have renal cell carcinoma or melanoma.  They are just the worst cancers."  You think YOU hate dealing with it, buddy!!!!  But, I digress...  We already know that treatment options for melanoma patients made huge strides with ipilimumab (Yervoy) and its 15% response rate.  We were over-the-moon with the 40% response rates attained with the anti-PD-1 products (Nivolumab/Opdivo and Pembrolizumab/Keytruda)!  Folks with urothelial cancers and NSCLC (non small cell lung cancer) benefited as well.  Still, no matter how great a 40% response rate is for some of us melanoma peeps...it sure leaves a lot of folks....60% of us to be exact...with no help!!!

Researchers worked to fill the void!!  The major working premise became ~ find something to add to immunotherapy to boost the response rate!  IDO inhibitors looked super promising.  Melanoma Big Dogs agreed.  Preliminary trials looked really good.  But then, not so much.  Here's a link that covers a post I made regarding the rise and fall of epacadostat:  Such a bummer!!!! An apparent end to the ECHO 301 trial testing epacadostat (an IDO inhibitor) combined with the anti-PD-1 product Keytruda (pembrolizumab) for melanoma

Here is another bit of an "op-ed" (not by me) about the conundrum of how to improve immunotherapy:  The difficult search for the right recipe in cancer immunotherapy

Yet, there are those who think that IDO inhibitors, perhaps even epacadostat itself, still hold promise and one poor showing doesn't mean they should be given the boot:  Sciencemag.org - A promising new cancer drug has hit a major setback, raising questions about whether the field is moving too fast

At any rate, back to NKTR-214 combined with nivo.  Like many drugs/trials in cancer/melanoma world, the Phase 1 trials were super promising.  Phase II results were a little less so.  Responses as noted in the article above were "(ORR) of 50% in treatment-naïve patients with melanoma, including an ORR of 42% in PD-L1–negative patients".  We have already determined that treatment naive patients tend to have the best responses.  But even so, 50% beats 40%.  Additionally, we also know that PD-L1 status has not been particularly definitive in attaining responses to anti-PD-1 drugs, but it is still good to note a 42% ORR in PD-L1 negative patients and that side effects were really no worse in this combo than when anti-PD-1 is taken alone.  So....

I still hold out hope ~ for vaccines, for IDO-inhibitors, and the current responses to NKTR-214 combined with nivo to hold.  BUT!  Unlike Melanoma Big Dogs in their ivory towers....we canaries in the coalmines...the ratties...you and me...can't afford to pontificate on the hypothetical.  We have to deal with the real live results that are happening for real.  Today.  To us.

Hang tough ratties.  And great thanks.  Love, c

Wednesday, August 19, 2020

TIL ACT for melanoma patients - past and present...


TIL, the use of tumor infiltrating lymphocytes, to treat melanoma has changed a good deal over the years.  Here's a bit of a review from 2016:  TIL - Tumor infiltrating lymphocytes

And these two reports from 2019:  Baseline levels of IL-9 predicted response to Adoptive cell therapy (ACT) using TIL in melanoma and a complete response in TIL paired with nivo (a case study)

A variety of reports follow.  First ~

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.  Dafni, Michielin, Lluesma, et al.  Ann Oncol.  2019 Dec 30.

Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been tested in advanced melanoma patients at various centers. We conducted a systematic review and meta-analysis to assess its efficacy on previously treated advanced metastatic cutaneous melanoma. The PubMed electronic database was searched from inception to 17 December 2018 to identify studies administering TIL-ACT and recombinant interleukin-2 (IL-2) following non-myeloablative chemotherapy in previously treated metastatic melanoma patients. Objective response rate (ORR) was the primary end point. Secondary end points were complete response rate (CRR), overall survival (OS), duration of response (DOR) and toxicity. Pooled estimates were derived from fixed or random effect models, depending on the amount of heterogeneity detected. Analysis was carried out separately for high dose (HD) and low dose (LD) IL-2. Sensitivity analyses were carried out. Among 1211 records screened, 13 studies (published 1988 - 2016) were eligible for meta-analysis. Among 410 heavily pretreated patients (some with brain metastasis), 332 received HD-IL-2 and 78 LD-IL-2. The pooled overall ORR estimate was 41% [95% confidence interval (CI) 35% to 48%], and the overall CRR was 12%. For the HD-IL-2 group, the ORR was 43%, while for the LD-IL-2 it was 35%. Corresponding pooled estimates for CRR were 14% and 7%. The majority of HD-IL-2 complete responders (27/28) remained in remission during the extent of follow-up after CR (median 40 months). Sensitivity analyses yielded similar results. Higher number of infused cells was associated with a favorable response. The ORR for HD-IL-2 compared favorably with the nivolumab/ipilimumab combination following anti-PD-1 failure. TIL-ACT therapy, especially when combined with HD-IL-2, achieves durable clinical benefit and warrants further investigation. We discuss the current position of TIL-ACT in the therapy of advanced melanoma, particularly in the era of immune checkpoint blockade therapy, and review future opportunities for improvement of this approach.

~ and now there is this out of UCLA, Jan 30, 2020:  Researchers identify possible new combination treatment for advanced melanoma

A study by researchers at the UCLA Jonsson Comprehensive Cancer Center suggests that using an immunotherapy drug called NKTR-214, also known as bempegaldesleukin, in combination with an infusion of anti-tumor immune cells, or T cells, may produce a stronger immune response that could help fight advanced melanoma.
When tested in mice with melanoma tumors that were unlikely to stimulate an immune response, the approach increased the number of anti-tumor immune cells, and those immune cells lived longer and functioned better than the standard therapy, empowering the cells to destroy the tumor.
Adoptive cell therapy is a type of immunotherapy that has had promising results for treating people with advanced cancers. The approach involves extracting and harvesting immune cells from a patient and engineering them in the laboratory to attack specific antigens on the surface of tumors. One challenge is that it requires giving patients interleukin 2, a protein signaling molecule in the immune system, to promote the development and expansion of the infused immune cells. But interleukin 2 can also activate cells to suppress the immune system, and because it is highly toxic, it can have serious adverse side effects.
Researchers have been seeking ways to produce large number of immune cells without exposing patients to those negative side effects — including by combining adoptive cell therapy with other treatments.
Researchers used mice to test NKTR-214 in combination with adoptive cell therapy. Using bioluminescence imaging, the researchers tracked the movement of T cells in the mice that received the combination therapy. The team observed an expansion of T cells in the spleen, the organ that helps accelerate the activation and expansion of T cells throughout the body. The T cells then migrated to the tumor, where they continued to have a long-lasting effect. The in vivo expansion and T cell accumulation in tumors was greatly improved when using NKTR-214 compared to using interleukin-2.
While immunotherapy has changed the face of cancer treatment for people with advanced cancers, it still only works in a small subset of patients. The results of the UCLA study suggest that using NKTR-214 in combination with adoptive cell therapy could be effective for more people with advanced solid tumors.  The study’s senior author is Dr. Antoni Ribas.
For some background on NKTR-214, there are these reports:  NKTR- 214 (bempegaldesleukin) with Opdivo

And finally, this ~

Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.  Besseer, Itzhaki, Ben-Betaalel, et al. Mol Carcinog. 2020 Apr 6. 

Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) mediates objective responses in 30% to 50% of patients with metastatic melanoma according to multiple, small phase 2 trials. Here we report the long-term clinical results, intent-to-treat analysis, predictors of response and toxicity profile in a large patient cohort. A total of 179 refractory melanoma patients were enrolled in the ACT trial. TIL were administered in combination with high-dose bolus interleukin-2 following preconditioning with cyclophosphamide and fludarabine. Patients were followed-up for a median of 7.2 years. A total of 107 (60%) of 179 enrolled patients were treated. The main reason for the drop out of the study was clinical deterioration. Of 103 evaluated patients, 29 patients (28%) achieved an objective response (OR), including complete remission (8%) or partial response (20%). Sixteen pateints exhibited stable disease. Predictors of response were performance status, time of TIL in culture and CD8 frequency in the infusion product. The absolute lymphocyte count 1 and 2 weeks after TIL infusion was the most predictive parameter of response. With a medium follow-up time of 7.2 years, OR patients reached a median overall survival (OS) of 58.45 months and a median progression-free survival (PFS) of 15.43 months, as compared with nonresponders, with 6.73 months OS and 2.60 months PFS. By 6 years, 50% of OR patients were alive and 43% had no documented progression. TIL ACT can yield durable objective responses, even as salvage therapy in highly advanced metastatic melanoma patients.

We've come a long way, baby!  But we have so much further to go!  For what it's worth. - c

Late addition!  There is also this report out of UPMC Hillman Cancer Center:  Udai Kammula, MD: Adoptive Cell Transfer Immunotherapy: Building on a Blueprint Provided by Studies of Metastatic Uveal Melanoma  Thanks, Edster!

Sunday, June 23, 2019

New Stuff!! Treatment options and current trials for melanoma patients! The first installment of this year's ASCO review.


As I expected, there was not a great deal of NEW news for melanoma patients coming out of ASCO this year.  However, there were a few new things in the works as well as supporting and dismissive data - (this last often being under reported, but certainly important!!!) - for some existing ideas/treatment strategies.  Over the next few days I will be posting some of the hits and misses (from my perspective) with my take (in red).  Here we go....

#1:  I first reported on NKTR in 2013.  Click here for that report as well as abstracts and analysis from 2018.  After examining the Phase 1 and Phase 2 reports of the PIVOT trial I wrote:

"...back to NKTR-214 combined with nivo.  Like many drugs/trials in cancer/melanoma world, the Phase 1 trials were super promising.  Phase II results were a little less so.  Responses as noted in the article were "(ORR) of 50% in treatment-naïve patients with melanoma, including an ORR of 42% in PD-L1–negative patients".  We have already determined that treatment naive patients tend to have the best responses.  But even so, 50% beats 40%.  Additionally, we also know that PD-L1 status has not been particularly definitive in attaining responses to anti-PD-1 drugs, but it is still good to note a 42% ORR in PD-L1 negative patients and that side effects were really no worse in this combo than when anti-PD-1 is taken alone.  So....

I still hold out hope ~ for vaccines, for IDO-inhibitors, and the current responses to NKTR-214 combined with nivo to hold.  BUT!  Unlike Melanoma Big Dogs in their ivory towers....we canaries in the coalmines...the ratties...you and me...can't afford to pontificate on the hypothetical.  We have to deal with the real live results that are happening for real.  Today.  To us."

That's how I look at melanoma research!!!!   ALWAYS! Now....this:

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).  2019 ASCO.  Nikhil, Khushalani, Diab, .... Sznol, Long.  J Clin Oncol 37, 2019 (suppl; abstr TPS9601)

Background: Standard of care for pts with previously untreated, unresectable or metastatic MEL includes checkpoint inhibitors. Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to provide sustained signaling through the IL-2 βγ receptor to activate and proliferate effector CD8+ T and NK cells over T-regulatory cells in the tumor (Hurwitz ME et al. ASCO GU 2017). In the dose-expansion phase of the phase 1/2 PIVOT-02 trial, bempegaldesleukin + NIVO was well tolerated at the recommended phase 2 dose (RP2D; bempegaldesleukin 0.006 mg/kg IV Q3W + NIVO 360 mg IV Q3W), and previously untreated pts with MEL receiving the RP2D achieved an objective response rate (ORR) of 20/38 (53%) and a complete response of 9/38 (24%) by independent radiology review (Diab A et al. SITC 2018). Presented is the design of the first phase 3 trial in the bempegaldesleukin + NIVO development program in pts with previously untreated, unresectable or metastatic MEL. Methods: This phase 3, randomized, open-label study aims to evaluate the effectiveness, safety, and tolerability of bempegaldesleukin + NIVO (NCT03635983). Eligible pts are greater that/= to 2 y with histologically confirmed stage III (unresectable) or stage IV MEL and ECOG PS less that/= to 1 or Lansky PS greater than/= to 80% (minors 12-17 y). Pts are ineligible if they have active brain or leptomeningeal metastases, uveal MEL, or a recurrence within 6 mo of completing adjuvant treatment with any approved agent. Pts will be stratified by PD-L1 status (measured using PD-L1 IHC 28-8 pharmDx), BRAF mutation status, and lactate dehydrogenase level, and will be randomized to receive bempegaldesleukin 0.006 mg/kg IV Q3W + NIVO 360 mg IV Q3W or NIVO 360 mg IV Q3W up to 24 mo, or until progression or unacceptable toxicity (N ~ 764). Primary endpoints are ORR and progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS). Secondary endpoints include ORR and PFS by investigator, ORR and PFS by BICR in biomarker population, OS in biomarker population, and safety. Additional endpoints include pharmacokinetics and quality-of-life assessment. Clinical trial information: NCT03635983

So, this is an open and recruiting trial.  It is randomized.  Some folks will be getting the NKTR-214 drug with nivo, some will get nivo only.  Prior ORR of 53% is better than the usual of about 40% to anti-PD-1 products given alone, but about equal to the ipi/nivo combo.  If the side effects of this combo is less than those caused by ipi/nivo, that could be a good thing.  Lots of the usual melanoma peeps are excluded.  But, there you go.

#2: In 2017, I posted:  IMO-2125, a TLR agonist combined with Yervoy (ipi) for folks with melanoma refractory to anti-PD-1 - writing:

"Hmmm.....  Well, it is certainly a fact that we have folks who fail to gain effective control of their melanoma with anti-PD-1 and its 40% response rate, leaving them in desperate need of an effective therapy!  It is also true that I encourage and fully support looking at any and all possible treatments to help them.  Yet, I remain a little puzzled here.  This statement sounds strong, but is substantially lacking in, hmmm....what's the word??????  "...data from multiple parameters of immune markers from tumor biopsies have been very informative in establishing proof-of-mechanism and supporting the dose selection for the Phase 2 portion of the trial.”  Oh!  I know what it is....DATA!!!!!!!!!!!!!!!  This report tells us NOTHING about how the folks in the phase 1 trial are doing!!!

An interesting aside:  The name TLR, toll-like receptor, came from the appearance the fruit fly larvae developed when used as subjects by researchers to isolate the molecule's function.  The larvae in whom the receptor was changed, looked very peculiar, or "droll", according to the German researchers who won a Nobel prize in medicine for this work.  And the German word for "droll" (i.e. funny) is "toll"!  The more you know....

While I hope IMO-2125 will absolutely be the cure for ever so many cancers, including melanoma, we need to remember that current intratumoral/intralesional therapies that are being combined with immunotherapy daily, to good effect, are available for melanoma patients in need and come WITH data supporting their efficacy!  Here's a post reviewing a wide variety of them and the DATA required for them to sally forth:

ASCO 2017: All things intralesional/intratumoral

If TLR agonists become the next great thing....will we all be cured of our melanoma AND have a great sense of humor...or just look a little funny?????  Hang tough ratties!  The road is long with lots of tolls!  And I mean LOTS!!! - c"

Now, there's this:

ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.  2019 ASCO.  Butler, Rober, Negrier....Ascierto, et al.  J Clin Oncol 37, 2019 (suppl; abstr TPS9599)

Background: Tilsotolimod (IMO-2125) is a Toll-like receptor (TLR) 9 agonist with potent immunostimulating activity. In an ongoing Phase 1/2 clinical study in patients with advanced melanoma who progressed on or after anti-PD-1 therapy (NCT02644967), intratumoral (IT) tilsotolimod with ipilimumab was well-tolerated, demonstrating durable responses (including complete response; 21 months), dendritic cell activation, type I interferon response, CD8+ T-cell proliferation in responders, and an abscopal effect. Methods: ILLUMINATE 301 (NCT03445533) is a randomized phase 3 global, multi-center, open-label study of IT tilsotolimod (8 mg) in combination with ipilimumab (3 mg/kg) versus ipilimumab monotherapy in patients with advanced melanoma and progression on or after anti-PD-1 therapy. Eligible patients are greater than/= to 18 years with histologically confirmed unresectable Stage III or Stage IV melanoma, greater than/= to 1 measurable lesion accessible for injection (superficial or visceral, the latter with image guidance), ECOG PS 1, and adequate organ function. Exclusion criteria include prior TLR agonists, prior ipilimumab (except adjuvant ≥12 weeks before progression), and CNS disease other than stable brain metastases. Patients are randomized 1:1 and stratified by duration of prior anti-PD-1.

So....another recruiting option for those who have progressed on anti-PD-1 and have an injectable lesions.  Stage III or IV melanoma ratties will be randomized to get either injections of tilsotolimod  (IMO-2125) directly into their lesion along with ipi or ipi alone.  You cannot have already taken a TLR agonist, ipi (unless it was only as adjuvant more than 12 weeks before progression) and can have no CNS disease other than stable brain mets.


A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.  2019 ASCO.  Hellmann, Shimizu, Toshihiko, Hodi, et al.  J Clin Oncol 37, 2019.

Background: Programmed cell death 1 immune checkpoint inhibitors (anti-PD-1, anti-PD-L1) have demonstrated clinical benefit in a subset of patients with manageable safety across a variety of tumor types. T-cell immunoglobulin and mucin-domain-containing molecule-3 (TIM-3) can be co-expressed with PD-1 on exhausted T-cells and may be upregulated in tumors refractory to anti-PD-1 therapy (Koyama et al. 2016). Pre-clinical studies demonstrated that blockade of both PD-1 and TIM-3 improved survival of tumor-bearing mice compared to blocking anti-PD-1 only (Koyama et al. 2016). LY3415244 is a TIM-3/PD-L1 bispecific antibody that has the ability to target and inhibit both TIM-3 and PD-L1 and the potential to overcome primary and acquired anti-PD-(L)1 resistance by a novel mechanism to bridge TIM-3- and PD-L1-expressing cells. Methods: Study JZDA is a multicenter, nonrandomized, open-label, Phase 1a/1b study of LY3415244 in patients with advanced solid tumors. In Phase 1a, subjects with any tumor type who are either PD-(L)1 inhibitor-naïve or exposed are eligible. In Phase 1b, expansion cohorts are planned in subjects with PD-(L)1-experienced NSCLC, urothelial carcinoma, and melanoma. Patients with malignant mesothelioma are not required to have received prior anti-PD-(L)1 therapy. The primary objective is to assess safety and tolerability of LY3415244 and identify the recommended Phase 2 dose (RP2D) in Phase 1a (dose escalation). Safety and tolerability of the RP2D will be assessed in Phase 1b (dose expansion). The secondary objectives are to assess the pharmacokinetics of LY3415244 in Phase 1a/1b and assess early antitumor activity of LY3415244 in Phase 1b cohorts. Pre- and on-treatment biopsies will be obtained to explore potential biomarkers of response. During Phase 1a, dose escalation cohorts will proceed via a modified toxicity probability interval-2 (mTPI-2) design with a 1-cycle (28-day) dose-limiting toxicity (DLT) observation period. LY3415244 will be dosed intravenously every 2 weeks. Data from Phase 1a will determine the RP2D, which will be used for all cohorts in Phase 1b. The study is currently open to enrollment. Clinical trial information: NCT03752177.

I seems that you can already have had anti-PD-1, or not, and still qualify.  Folks with NSCLC, urothelial carcinoma or melanoma may enter.  Initially, it is a just a dose limiting study...how much can you give without making folks grow 2 heads?...but then they are also going to look at the impact on the tumors as well.  Early days for this one, but....

#4:  TNF is tumor necrosis factor is a protein that plays a role in cell life, differentiation, growth, and death and has a lot to do with inflammation in our bodies.  In cancer, it's even more complicated.  In this article, the authors note: "In regard to cancer, TNF is a double-dealer. On one hand, TNF could be an endogenous tumor promoter, because TNF stimulates cancer cells’ growth, proliferation, invasion and metastasis, and tumor angiogenesis. On the other hand, TNF could be a cancer killer. The property of TNF in inducing cancer cell death renders it a potential cancer therapeutic, although much work is needed to reduce its toxicity for systematic TNF administration. Recent studies have focused on sensitizing cancer cells to TNF-induced apoptosis through inhibiting survival signals such as NF-κB, by combined therapy."

Now, there's this:

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.  Perez-Ruiz, Minute, Otano, et al.  Nature. 2019 May 1. 

Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer. However, this comes at the cost of frequent, serious immune-related adverse events, necessitating a reduction in the recommended dose of ipilimumab that is given to patients. In mice, co-treatment with surrogate anti-PD-1 and anti-CTLA-4 monoclonal antibodies is effective in transplantable cancer models, but also exacerbates autoimmune colitis. Here we show that treating mice with clinically available TNF inhibitors concomitantly with combined CTLA-4 and PD-1 immunotherapy ameliorates colitis and, in addition, improves anti-tumour efficacy. Notably, TNF is upregulated in the intestine of patients suffering from colitis after dual ipilimumab and nivolumab treatment. We created a model in which Rag2-/-Il2rg-/- mice were adoptively transferred with human peripheral blood mononuclear cells, causing graft-versus-host disease that was further exacerbated by ipilimumab and nivolumab treatment. When human colon cancer cells were xenografted into these mice, prophylactic blockade of human TNF improved colitis and hepatitis in xenografted mice, and moreover, immunotherapeutic control of xenografted tumours was retained. Our results provide clinically feasible strategies to dissociate efficacy and toxicity in the use of combined immune checkpoint blockade for cancer immunotherapy.

Knowing that TNF is "upregulated in the intestines of patients suffering from colitis" due to ipi/nivo, these researchers gave mice a TNF inhibitor BEFORE treating them with ipi/nivo.  Per this report, blocking TNF improved episodes of colitis and hepatitis caused by ipi/nivo in these poor mice AND the ipi/nivo was still effective against their tumors.  Let's hope it works in real live ratties!!

#5:  TIL is complicated in lots of ways.  I posted this in 2016:  TIL - Tumor infiltrating lymphocytes  writing in part:

"What is TIL?  TIL (Tumor infiltrating lymphocytes) are used in an ACT (adoptive cell transfer) therapy like this:  A tumor is removed from the patient's body.  Lymphocytes are collected from it.  Those lymphocytes are tested in order to identify the cells that show the greatest anti-tumor activity.  Then....those particular cells are grown in a lab for several weeks.  If the TIL cells grow sufficiently, the patient is given a body pounding dosing of chemotherapy to rid the body of other lymphocytes so that the new TIL batch will be accepted more readily when they are infused with no other immune cells there to attack them.  The newly grown lymphocytes are then returned to the patient in an infusion along with a cytokine (immune stimulating agent) like IL2 (interleukin 2).  In numerous studies TIL demonstrates a 50% response rate in patients with metastatic melanoma."

"So....basically.  A tumor is harvested.  T-cells are extracted from it...with the idea that they were good soldiers who had already recognized and were in the process of attacking that tumor.  To increase their numbers...they are grown in a dish.  To further their interests...the patient (ie the battlefield) is injected with bad stuff (IL-2, IL-21, or cyclophosphomide and fludarabine, are frequently used) to kill off T-cells that might try to block their fight with the tumor...and/or support the good T-cells...which are then sent back into battle (ie injected into the patient)!" 

Further, I posted this earlier this year:  Baseline levels of IL-9 predicted response to Adoptive cell therapy (ACT) using TIL in melanoma and a complete response in TIL paired with nivo (a case study)  Where it was noted that:  "Best overall response for the entire cohort was 42%; 47% in 43 checkpoint naïve patients, 38% when patients were exposed to anti-CTLA4 alone (21 patients) and 33% if also exposed to anti-PD1 (9 patients) prior to TIL ACT. Median overall survival was 17.3 months; 24.6 months in CTLA4 naïve patients and 8.6 months in patients with prior CTLA4 blockade. "

Growing useful cells to be injected back to the patient is tricky and just one of many obstacles in TIL therapy.  As the process has advanced, it has diverged into a variety of techniques and methods that can be utilized.  Now, there's this:

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.  2019 ASCO.  Sasnaik, Nikhill,Khushalani, et al.  J Clin Oncol 37, 2019 (suppl; abstr 2518)

Background: Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E mutated). Adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable long-term responses in heavily pretreated melanoma patients. Safety and efficacy of lifileucel (LN-144), a centrally manufactured autologous TIL therapy are presented. Methods: C-144-01 is a global Phase 2 open-label, multicenter study of the efficacy and safety of lifileucel in patients with unresectable metastatic melanoma. We report on Cohort 2 (N = 55) patients who received cryopreserved lifileucel. Tumors resected at local institutions were processed in central GMP facilities for TIL production in a 22-day process. Final TIL infusion product was cryopreserved and shipped to sites. Patients received one week of cyclophosphamide/fludarabine preconditioning lymphodepletion, a single lifileucel infusion, followed by up to 6 doses of IL-2. Results: In 55 patients with Stage IIIC/IV unresectable melanoma, 3.1 mean prior therapies (anti-PD1 100%; anti-CTLA-4 80%; BRAF/MEK inhibitor 24%), high baseline tumor burden (110 mm mean target lesion sum of diameters), ORR was 38% (2 CR, 18 PR, 1 uPR). Of 21 responders, 4 have progressed to date with median follow up of 7.4 months. Overall disease control was 76%. Improved responses in some patients were observed with longer follow up. Most (54) patients progressed on prior anti-PD1 and those with PD-L1 negative status were among responders. Mean cells infused was 28 x109. Median IL-2 doses administered was 6.0. Adverse events resolved to baseline, 2 weeks post TIL infusion, a potentially important benefit of one-time TIL therapy. Conclusions: Lifileucel treatment results in 38% ORR in heavily pretreated metastatic melanoma patients with high baseline disease burden who received prior anti-PD1 and BRAF/MEK inhibitor if BRAF mutated. Based on these data, a new Cohort 4 in C-144-01 has been initiated to support lifileucel registration. Clinical trial information: NCT0236057

Here 55 Stage III/IV melanoma patients previously treated with anti-PD-1, ipi, and/or BRAF/MEK, with progressive disease and high tumor burden were given "cryopreserved lifileucel" derived from "tumors resected" at several institutions, then "processed" at a central facility for "TIL production in a 22-day process" then "cryopreserved and shipped to sites".  As is typical with TIL therapy, patients were given one of the nasty pre-treatment concoctions to kill off their existing lymphocytes, were then given a single infusion of lifileucel, followed by up to 6 doses of hell (I mean IL-2).  ORR = 38%.  Of 21 initial responders, 4 have progressed over the f/u of 7.4 months.  Overall disease control was 76%.  Both folks who had progressed on anti-PD-1 and those with PD-L1 negative status were among the responders.  Based on this result, a new cohort is recruiting.

#6:  The "microbiome" craze is not exactly 'new' as it has taken over the universe! BUT!!!  How much is hype?  How much is real?  How can we drill down on the details?  How can we harness what we know to impact treatments such that patients benefit?  The next 3 posts address this topic.  Now, there's this:

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.  2019 ASCO.  Shubham, Imke, Amishi, et al. J Clin Oncol 37, 2019 (suppl; abstr TPS2670) 

Background: The gut microbiome has emerged as a new therapeutic target to augment the efficacy of immune checkpoint blockade. MRx0518 is a novel, gut microbiome-derived, oral live biotherapeutic, designed to induce a broad immunostimulatory response to re-engage PD-1 inhibitor activity. Preclinical studies showed that MRx0518 reduced tumour growth in models of kidney, lung and breast cancer. MRx0518 increased CD4 and CD8 T cell and NK cell infiltration into the tumour and decreased Tregs. Upregulation of tumour TLR5 was observed and linked to the bacterial flagellin moiety, which was shown to strongly induce NFκB, cytokine responses and IFNγ+ CD4 and CD8 T cells. The study, one of the first oncology trials conducted with live biotherapeutics, is a single center, open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumors who have progressed on PD-1 inhibitors. Methods: Trial consists of 2 parts. In Part A, 12 patients receive pembrolizumab 200 mg every 3 weeks plus 1 capsule (bid) of MRx0518 with a DLT period of 1 cycle (21 days). In Part B, up to 30 patients per cohort (NSCLC, Urothelial, Renal and Melanoma) will receive pembrolizumab 200 mg every 3 weeks plus 1 capsule (bid) of MRx0518 for up to 35 cycles or until disease progression per RECIST 1.1. The primary end points are safety and tolerability of MRx0518 in combination with pembrolizumab (Parts A and B) and clinical benefit of MRx0518 in combination with pembrolizumab (Part B). Secondary end points are objective response rate, duration of response, disease control rate, and progression-free survival. Exploratory end points include biomarkers of treatment effect, effect on microbiota and overall survival. Recruitment is ongoing. Clinical trial information: NCT03637803

Here, researchers are going to give the first 12 patients with solid tumors who have progressed on anti-PD-1, Pembro every 3 weeks along with a capsule of MRx0518, a "live biotherapeutic", taken by mouth, twice a day for one 21 day cycle.  In part b, the plan is that 30 patients could be given the same for up to 35 cycles or until disease progression.  My only concern here would be the fact that we've found that folks who took probiotics from a bottle did not do so well, while those that got their cooties from foods like Kefir, kimchi, yogurt, sauerkraut, etc. - did better.  If I were to consider participation in this study, I'd be asking my doc about that.

#7:  As I noted above, these last two reports are more along the lines of ~ "What once was old is new again!" I've been talking about the Cooties in our Gut since 2015, putting it all together in this post from 2018:  Microbes again...and how they may be associated with improved response to anti-PD-1 for melanoma patients...and you might even laugh!!!  Still, there is much we don't understand about how all this works.  Now, there's this:

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.  Li, Tinoco, Elmen, et al.  Nat Commun. 2019 Apr 2.

Accumulating evidence points to an important role for the gut microbiome in anti-tumor immunity. Here, we show that altered intestinal microbiota contributes to anti-tumor immunity, limiting tumor expansion. Mice lacking the ubiquitin ligase RNF5 exhibit attenuated activation of the unfolded protein response (UPR) components, which coincides with increased expression of inflammasome components, recruitment and activation of dendritic cells and reduced expression of antimicrobial peptides in intestinal epithelial cells. Reduced UPR expression is also seen in murine and human melanoma tumor specimens that responded to immune checkpoint therapy. Co-housing of Rnf5-/- and WT mice abolishes the anti-tumor immunity and tumor inhibition phenotype, whereas transfer of 11 bacterial strains, including B. rodentium, enriched in Rnf5-/- mice, establishes anti-tumor immunity and restricts melanoma growth in germ-free WT mice. Altered UPR signaling, exemplified in Rnf5-/- mice, coincides with altered gut microbiota composition and anti-tumor immunity to control melanoma growth.

So, a lot of fancy words to say that mice with a certain microbiome component (less UPR expression) responded better to immunotherapy.  Further, when those mice lived with mice whose gut initially did not possess those properties, researchers found that they too developed an altered gut flora and a greater ability to restrict the growth of melanoma.  Bottom line:  Live with somebody who has the right cooties!  (If you can figure out who exactly that is!!!)

#8:  Given the fact that a certain "microbiome" aids our responses to immunotherapy while a different one does not, it makes sense that antibiotics, which kill off bacteria that are trying to do us harm as well as those who may do a body good, could be problematic when trying to foster cooties that improve our response to immunotherapy.  Here are some earlier articles and explanations:

This from 2017:  Antibiotic use MAY decrease effectiveness of immunotherapy?????

And this from April of this year:  DECREASED progression free survival in melanoma patients treated with antibiotics prior to or at start of immunotherapy!!!!  In that study it was noted that, despite - "Small numbers. ..the 10 folks, from the 74 advanced melanoma peeps examined, who were given antibiotics within 30 days of their immunotherapy, had more resistance to treatment, a shorter length of progression free survival (2.4 vs 7.3 months) and overall survival was shorter at 10.7 months vs 18.3 months." 

Now, there's this:

Effect of antibiotic exposure in patients with metastatic melanoma treated with PD-1 inhibitor or CTLA-4 inhibitor or a combination of both.  2019 ASCO. Kapoor, Runnels, Boyce, et al.  J Clin Oncol 37, 2019 (suppl; abstr e14141)

Background: Pre clinical studies have demonstrated the effect of gut microbiome in the efficacy of immune check point inhibitors. The effect of antibiotic exposure to patients receiving PD-1/CTLA-4 inhibitor therapy has not been extensively studied, especially in metastatic melanoma. In this study, we demonstrate the effect of antibiotic exposure to metastatic melanoma patients receiving PD-1/CTLA-4 inhibitor therapy. Methods: We performed a retrospective analysis of 108 patients with stage 4 metastatic melanoma who received immunotherapy with PD-1 inhibitors or CTLA-4 inhibitors or combination of both between Nov 2010 and Oct 2017. Patients were divided into Abx(+) and Abx(-) groups that were defined as patients exposed or not exposed to antibiotics respectively. The time frame for antibiotic exposure was taken from 6 months prior to 1 month after initiation of immunotherapy. We compared progression free survival (PFS), overall survival (OS) and response rate (RR) between the two groups. RR was calculated based on the entire length of follow-up.  Results: Out of 108 patients, 66 were men, with a mean age 64.6 ± 15.1 years. 46 patients were exposed to antibiotics of varied classes. Median PFS in abx(+) group [88 days] was shorter as compared to abx(-) group [322 days]. Patients in abx(-) group had a 68% reduced risk of progression within 200 days of immunotherapy initiation adjusting for sex, age and number of immunotherapy cycles . Median OS in ab(+) group [294 days] was shorter as compared to abx(-) group [573 days]. Response rate defined as percentage of patients whose cancer was stable or entered remission was 12.9% in abx(-) group as compared to 8.7% ab(+) group. Patients in abx(-) group had a 52% reduced risk of death adjusting for sex, age and number of immunotherapy cycles. Conclusions: Antibiotic exposure is associated with poorer outcomes in patients with advanced metastatic melanoma being treated with PD-1/CTLA-4 inhibitors which is likely related to alteration of gut microbiome. Antibiotics should be prescribed with caution in patients undergoing treatment with immune check point inhibitors. These data should be validated in a larger patient population.

In this retrospective study of 108 melanoma patients treated with immunotherapy, it was noted that 46 were given antibiotics at some point between 6 months prior and 1 month after starting their immunotherapy treatment.  PFS was 88 days in those who took antibiotics and 322 days in the group who didn't.  OS was 294 days in the antibiotic group - 573 days in the non-antibiotic group.  Response rate was 8.7% in the group that had taken antibiotics vs 12.9% in the group that had not been exposed to antibiotics.  As I wrote in the post I put up in April:  "So...if you really NEED antibiotics, they may save your life and will certainly decrease misery. BUT, if you DON'T really NEED them...they can cause harm, in lots of ways."

WHEW!!!  Melanoma is a lot.  A lot of crap.  And an actual crap shoot for far too many!  But, just like today...


...there is still beauty, despite the storm.

More to come. c

Saturday, April 16, 2022

The BUSINESS of Cancer - BMS and Nektar ending immuno-oncology program?

 

I've written about NKTR-214 (bempegaldesleukin) since 2013. 

There was this ~ regarding the NKTR/Opdivo combo trial, PIVOT, from 2018:  ASCO 2018 - PIVOT, PIVOT, PIVOT!!!!! (Sorry, FRIENDS flashback to Ross moving a couch in a stairwell!!!) But, really - NKTR-214 plus nivo

This report ~ covering the incredible muckup regarding some batches of Bempeg being "substandard" because they were "out of specification" resulting in "lower results for patients" in an astonishing interview Nektar CEO Howard Robin gave to FiercePharma in 2019:  NKTR- 214 (bempegaldesleukin) with Opdivo - PERHAPS the results from the PIVOT trial for melanoma patients were LOWER than they should have been? Meaning if the company who makes it (Nektar) gets its act together patients may demonstrate an even better response????

And in 2020 there was this report ~ in which Bempeg was used in TIL (on mice):  TIL ACT for melanoma patients - past and present...

Now, there's this ~  Game over: Bristol Myers, Nektar end $3.6B immuno-oncology program after 2 more late-stage flops, a report by Nick Paul Taylor, April 15, 2022, from FIERCEBiotech, which reads:

Bristol Myers Squibb and Nektar have read the last rites to their huge, failed cancer collaboration. With two more late-stage trials failing, the partners have ended clinical development of a combination they once saw as the future of immuno-oncology.  The chances of Bristol Myers’ $1 billion upfront bet on bempegaldesleukin, a prodrug of PEGylated IL-2, paying off shrank last month. One month ago, Bristol Myers revealed a combination of Nektar’s bempeg and its Opdivo failed to improve on the progression-free survival and objective response rate achieved by the PD-1 checkpoint inhibitor as a single agent in previously untreated melanoma patients. The failure triggered the end of another study and raised serious doubts about the future of the combination. 

Bristol Myers and Nektar confirmed those doubts late Thursday, revealing the combination has failed in two other clinical trials. In one study, the partners compared their drug cocktail to the investigator’s choice of two tyrosine kinase inhibitors (TKIs), namely Exelixis’ Cabometyx and Pfizer’s Sutent, in metastatic renal cell carcinoma (RCC) patients. The trial looked at intermediate/poor risk and all-risk populations.  

A preplanned interim analysis found the investigational combination failed to improve on the overall survival achieved by the TKIs in either population. Faced with the failure, Bristol Myers and Nektar have decided to unblind the trial and perform no more overall survival analyses.

Bristol Myers and Nektar also reported the failure of the combination in patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer. The single-arm phase 2 clinical trial failed to achieve the objective response rate needed to support the continuation of the program.

After going 0 for 3, Bristol Myers and Nektar have decided to discontinue all other studies of the drug combination. The list of studies now winding down include a pivotal program in muscle-invasive bladder cancer and a pair of phase 1/2 trials in RCC and pediatric tumors. Shares in Nektar fell 17% to around $5 after hours, wiping out the small gains they made after news of the melanoma failure dropped.  

The discontinuation of the clinical development program confirms the failure of one of the big bets of Thomas Lynch's time as Bristol Myers’ chief scientific officer. Bristol Myers paid $1 billion upfront, made a $850 million stock purchase at $102.60 a share—a price it only briefly hit in the immediate afterglow of the deal—and committed up to $1.8 billion in milestones, all for a 35% split of global profits. 

Bristol Myers put together the mammoth financial package in the belief IL-2 was one of three validated mechanisms in immuno-oncology, the others being PD-1 and CTLA-4. The IL-2 cytokine is the first cancer immunotherapy, with the FDA approving a recombinant form in the early 1990s, but problems such as its poor drug-like properties and toxicity limited uptake. Bempeg was designed to eliminate those problems. 

Now - This report is from a source that looks only at the money making aspect of medicine.  The existence of this publication ~ FIERCEBiotech ~ and their often first-to-publish accuracy (Over the years I've often found info regarding trials and drug development on their site long before I found it in medical journals!) speaks to the business of medicine.  The sad truth is that if the product isn't going to make money for the company in sufficient margins, then it isn't going to be produced on the 'free market'.  At times drugs have been protected when the government has stepped in - but that's a whole other story.  I am NOT certain (given the obvious crazy in the melanoma PIVOT trial) that the Opdivo/Bempeg combo, nor the use of Bempeg in melanoma affected mice given TIL, offered any real benefit to melanoma patients. Still, given the small share of the cancer market melanoma patients provide and the pronouncement in this article that Nektar and BMS are closing the doors on this immunotherapy combo, it seems unlikely that the PIVOT trial nor any others using Bempeg for melanoma patients will be completed, much less end up as a treatment option.

Hmmm.....  $$$$$!!!!  We'll see what happens. - c